Decision Diagnostics Corp (DECN) 0.1140 $DECN
Decision Diagnostics Emerges Victorious in End to Acrimonious Patent Litigation With Divisions of Johnson + Johnson
Marketwire Canada - Thu Jun 02, 8:20AM CDT
Company Now Focused on Critical Immediate and Future Tasks: Sales, New Product Development and Launch, Growth, Product Branding, and Winning Its Strategic Patent Suit in Nevada
Decision Diagnostics Nears Positive Ending of Its California Patent and Trademark Infringement Litigation With Divisions of Johnson + Johnson
Marketwired - Thu May 12, 8:20AM CDT
LOS ANGELES, CA--(Marketwired - May 12, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets, today reports two consequential updates in its nearly five year legal battle with two divisions of pharmaceutical industry giant Johnson + Johnson, who in September 2011 began a series of lawsuits based on false, and as ultimately demonstrated, frivolous legal allegations of patent and trademark infringement.
Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board". Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields.
Decision Diagnostics Engages Retail Monster LLC to Procure Big Box Retailers for Company's GenUltimate Product
Marketwired - Thu Apr 14, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J" LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) and GenChoice(TM) glucose test strips targeted to the U.S. and/or developing world markets, today announced the execution of a broad representation agreement with Retail Monster, LLC, a retail and marketing specialist firm with offices in CA, AR, FL, and NY.
Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions
Marketwired - Wed Mar 16, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J" LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV against Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) stipulating multiple incidences of infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400-$700 million.
JNJ: 124.46 (-0.31)
DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement
Marketwired - Mon Mar 14, 7:01PM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J" LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, Case 2:16-cv-00564, titled Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al which named Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) and alleged infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400 million.
JNJ: 124.46 (-0.31)
Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson
Marketwired - Tue Feb 09, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J" LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today relays a summary of the arguably illegitimate J&J/Lifescan lawsuit impact on DECN business activity, its current status and future expectations.
JNJ: 124.46 (-0.31)
DECN Assesses Its Recent Landmark Legal Victories Over Diabetes Division Of Johnson & Johnson
PR Newswire - Thu Jan 28, 8:57AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's ("J&J" LifeScan OneTouch Ultra family of glucose testing meters, today publishes the first of three detailed analyses concerning: 1) the legal history and current situation of the litigation with the division of J&J, 2) the most recent rulings and upcoming events and their implications to the company, and finally 3) the sea change in the business landscape brought about by the recent ruling. To summarize the current topics:
JNJ: 124.46 (-0.31)
Decision Diagnostics Wins Federal Appeals Court Victory, Ruling Affirms J&J Division's Loss of US Patent No. 7,250,105
Marketwired - Thu Jan 21, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that the United States Court of Appeals for the Federal Circuit has affirmed the Final Ruling of the USPTO court, bringing an end to a nearly three year challenge brought by the company's Pharma Tech Solutions, Inc. subsidiary against Lifescan Scotland Ltd. The company brought its action in 2013, disputing the patentability of claims 1-3 in U.S. Patent No. 7,250,105. The company won a Final Ruling in August 2014 "by a preponderance of the evidence" in a USPTO court process. The Federal Circuit's unanimous rejection of Lifescan's appellate motions through a Rule 36 summary affirmation unambiguously denies their petition and mitigates further legal challenge.
Decision Diagnostics Completes Investment in Korean R+D and Contract Manufacturing Partner
ACCESSWIRE - Sun Jun 14, 11:57PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 15, 2015 / Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that on May 29, 2015, we completed an investment in special manufacturing equipment in Korea at the facilities of the company's second contract manufacturer.
Decision Diagnostics signs manufacturing and R+D agreement for its proprietary blood glucose test strip with a Korean manufacturer
M2 - Fri Jun 05, 3:42AM CDT
Diagnostics products company Decision Diagnostics (OTC PINK
ECN) revealed on Thursday the launch of manufacturing and R+D agreement to supplement the supply of its proprietary blood glucose test strip through a Korean manufacturer.
Decision Diagnostics Executes Broad Manufacturing and R+D Agreement With Korean Manufacturer
Marketwired - Thu Jun 04, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced the selection and contracting of a Korean manufacturer to supplement the supply of the company's proprietary blood glucose test strip. The agreement also encompasses the co-development of multiple internally designed new products, a market ready meter system that utilizes the company's proprietary blood glucose test strip in export markets, and the distribution of an existing glucose monitoring system to the domestic at-home pet testing market. This agreement was activated through a cash investment by the Decision Diagnostics subsidiary Pharma Tech Solutions, Inc., in the Korean manufacturer.
Decision Diagnostics States Johnson & Johnson Division Offers Partial Surrender in Long Running Patent Battle
PR Newswire - Tue May 19, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that the company was approached on May 12, 2015 by the Lifescan division of health industry giant Johnson & Johnson for the company's stipulation to Lifescan/J&J's offer to agree to a dismissal of several critical counts in the long running patent infringement suit between the parties. Lifescan/J&J's offer included that their lawsuit counts listed below each be DISMISSED WITH PREJUDICE:
Decision Diagnostics submits application for uplisting to OTCMarkets OTCQX
M2 - Wed May 13, 4:14AM CDT
Decision Diagnostics (OTC PINKECN) said on Tuesday that it has submitted all pending financial applications for listing its securities to trade on OTCQX, a higher tier of the Over The Counter (OTC) markets, overseen by OTCMarkets.
Decision Diagnostics Files Application for Uplisting to OTCMarkets OTCQX
Marketwired - Tue May 12, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that it has applied for a listing for its securities to trade on OTCQX, a higher tier of the Over The Counter (OTC) markets, overseen by OTCMarkets, Inc.
Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case
PR Newswire - Tue Apr 21, 8:15AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that Johnson & Johnson/Lifescan has requested an unscheduled Case Management Conference in the U.S. District Court for the Northern District of California. Pharma Tech announced last week that the Solicitor General of the United States had noticed its intention to intervene in support of Pharma Tech's legal arguments in that recent Johnson & Johnson/Lifescan appeal. Transparently responding to that Solicitor General announcement, Johnson & Johnson/Lifescan has submitted a request for an unscheduled Case Management Conference to supposedly identify a path to conflict resolution. In actuality, it represents an overt effort to precipitate the court's final appeal ruling and to preclude the hearing of the evidence in the resultant anti-trust litigation.
JNJ: 124.46 (-0.31)
U.S. Solicitor General Intervenes Against Johnson & Johnson in DECN's Long Running Patent Battle Over GenStrip 50
Marketwired - Tue Apr 14, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Alternative Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that the United States government through its Solicitor General has intervened in the recent appeal filed by J&J/Lifescan in the United States Court of Appeals for the Federal Circuit (the patent appeals court).
JNJ: 124.46 (-0.31)
Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor
Marketwired - Tue Mar 31, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that Lifescan/J&J has filed its final appeal in the United States Court of Appeals for the Federal Circuit (the patent appeals court), in an effort to overturn an IPR (USPTO court) decision by the U.S. Patent and Trademark Office that Pharma Tech proved that all of the claims in J&J/Lifescan's U.S. Patent 7,250,105, are unpatentable.
JNJ: 124.46 (-0.31)
Decision Diagnostics Emerges Victorious in End to Acrimonious Patent Litigation With Divisions of Johnson + Johnson
Marketwire Canada - Thu Jun 02, 8:20AM CDT
Company Now Focused on Critical Immediate and Future Tasks: Sales, New Product Development and Launch, Growth, Product Branding, and Winning Its Strategic Patent Suit in Nevada
Decision Diagnostics Nears Positive Ending of Its California Patent and Trademark Infringement Litigation With Divisions of Johnson + Johnson
Marketwired - Thu May 12, 8:20AM CDT
LOS ANGELES, CA--(Marketwired - May 12, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets, today reports two consequential updates in its nearly five year legal battle with two divisions of pharmaceutical industry giant Johnson + Johnson, who in September 2011 began a series of lawsuits based on false, and as ultimately demonstrated, frivolous legal allegations of patent and trademark infringement. Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board". Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields. Decision Diagnostics Engages Retail Monster LLC to Procure Big Box Retailers for Company's GenUltimate Product
Marketwired - Thu Apr 14, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strips, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) and GenChoice(TM) glucose test strips targeted to the U.S. and/or developing world markets, today announced the execution of a broad representation agreement with Retail Monster, LLC, a retail and marketing specialist firm with offices in CA, AR, FL, and NY. Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions
Marketwired - Wed Mar 16, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV against Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) stipulating multiple incidences of infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400-$700 million. JNJ: 124.46 (-0.31)
DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement
Marketwired - Mon Mar 14, 7:01PM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, Case 2:16-cv-00564, titled Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al which named Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) and alleged infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400 million. JNJ: 124.46 (-0.31)
Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson
Marketwired - Tue Feb 09, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip(TM) 50 and the GenUltimate(TM) glucose test strip, both designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure(TM) glucose test strip targeted to the developing world markets, today relays a summary of the arguably illegitimate J&J/Lifescan lawsuit impact on DECN business activity, its current status and future expectations. JNJ: 124.46 (-0.31)
DECN Assesses Its Recent Landmark Legal Victories Over Diabetes Division Of Johnson & Johnson
PR Newswire - Thu Jan 28, 8:57AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's ("J&J"
LifeScan OneTouch Ultra family of glucose testing meters, today publishes the first of three detailed analyses concerning: 1) the legal history and current situation of the litigation with the division of J&J, 2) the most recent rulings and upcoming events and their implications to the company, and finally 3) the sea change in the business landscape brought about by the recent ruling. To summarize the current topics: JNJ: 124.46 (-0.31)
Decision Diagnostics Wins Federal Appeals Court Victory, Ruling Affirms J&J Division's Loss of US Patent No. 7,250,105
Marketwired - Thu Jan 21, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that the United States Court of Appeals for the Federal Circuit has affirmed the Final Ruling of the USPTO court, bringing an end to a nearly three year challenge brought by the company's Pharma Tech Solutions, Inc. subsidiary against Lifescan Scotland Ltd. The company brought its action in 2013, disputing the patentability of claims 1-3 in U.S. Patent No. 7,250,105. The company won a Final Ruling in August 2014 "by a preponderance of the evidence" in a USPTO court process. The Federal Circuit's unanimous rejection of Lifescan's appellate motions through a Rule 36 summary affirmation unambiguously denies their petition and mitigates further legal challenge.
Decision Diagnostics Completes Investment in Korean R+D and Contract Manufacturing Partner
ACCESSWIRE - Sun Jun 14, 11:57PM CDT
LOS ANGELES, CA / ACCESSWIRE / June 15, 2015 / Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that on May 29, 2015, we completed an investment in special manufacturing equipment in Korea at the facilities of the company's second contract manufacturer.
Decision Diagnostics signs manufacturing and R+D agreement for its proprietary blood glucose test strip with a Korean manufacturer
M2 - Fri Jun 05, 3:42AM CDT
Diagnostics products company Decision Diagnostics (OTC PINK
ECN) revealed on Thursday the launch of manufacturing and R+D agreement to supplement the supply of its proprietary blood glucose test strip through a Korean manufacturer. Decision Diagnostics Executes Broad Manufacturing and R+D Agreement With Korean Manufacturer
Marketwired - Thu Jun 04, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced the selection and contracting of a Korean manufacturer to supplement the supply of the company's proprietary blood glucose test strip. The agreement also encompasses the co-development of multiple internally designed new products, a market ready meter system that utilizes the company's proprietary blood glucose test strip in export markets, and the distribution of an existing glucose monitoring system to the domestic at-home pet testing market. This agreement was activated through a cash investment by the Decision Diagnostics subsidiary Pharma Tech Solutions, Inc., in the Korean manufacturer.
Decision Diagnostics States Johnson & Johnson Division Offers Partial Surrender in Long Running Patent Battle
PR Newswire - Tue May 19, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that the company was approached on May 12, 2015 by the Lifescan division of health industry giant Johnson & Johnson for the company's stipulation to Lifescan/J&J's offer to agree to a dismissal of several critical counts in the long running patent infringement suit between the parties. Lifescan/J&J's offer included that their lawsuit counts listed below each be DISMISSED WITH PREJUDICE:
Decision Diagnostics submits application for uplisting to OTCMarkets OTCQX
M2 - Wed May 13, 4:14AM CDT
Decision Diagnostics (OTC PINK
ECN) said on Tuesday that it has submitted all pending financial applications for listing its securities to trade on OTCQX, a higher tier of the Over The Counter (OTC) markets, overseen by OTCMarkets. Decision Diagnostics Files Application for Uplisting to OTCMarkets OTCQX
Marketwired - Tue May 12, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that it has applied for a listing for its securities to trade on OTCQX, a higher tier of the Over The Counter (OTC) markets, overseen by OTCMarkets, Inc.
Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case
PR Newswire - Tue Apr 21, 8:15AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that Johnson & Johnson/Lifescan has requested an unscheduled Case Management Conference in the U.S. District Court for the Northern District of California. Pharma Tech announced last week that the Solicitor General of the United States had noticed its intention to intervene in support of Pharma Tech's legal arguments in that recent Johnson & Johnson/Lifescan appeal. Transparently responding to that Solicitor General announcement, Johnson & Johnson/Lifescan has submitted a request for an unscheduled Case Management Conference to supposedly identify a path to conflict resolution. In actuality, it represents an overt effort to precipitate the court's final appeal ruling and to preclude the hearing of the evidence in the resultant anti-trust litigation.
JNJ: 124.46 (-0.31)
U.S. Solicitor General Intervenes Against Johnson & Johnson in DECN's Long Running Patent Battle Over GenStrip 50
Marketwired - Tue Apr 14, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Alternative Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that the United States government through its Solicitor General has intervened in the recent appeal filed by J&J/Lifescan in the United States Court of Appeals for the Federal Circuit (the patent appeals court).
JNJ: 124.46 (-0.31)
Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor
Marketwired - Tue Mar 31, 8:20AM CDT
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, today announced that Lifescan/J&J has filed its final appeal in the United States Court of Appeals for the Federal Circuit (the patent appeals court), in an effort to overturn an IPR (USPTO court) decision by the U.S. Patent and Trademark Office that Pharma Tech proved that all of the claims in J&J/Lifescan's U.S. Patent 7,250,105, are unpatentable.
JNJ: 124.46 (-0.31)
